Scynexis Overview
- Year Founded
-
1999
- Status
-
Public
- Employees
-
29
- Stock Symbol
-
SCYX
- Investments
-
1
- Share Price
-
$2.59
- (As of Thursday Closing)
Scynexis General Information
Description
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
Contact Information
Website
www.scynexis.comCorporate Office
- 1 Evertrust Plaza
- 13th Floor
- Jersey City, NJ 07302
- United States
Corporate Office
- 1 Evertrust Plaza
- 13th Floor
- Jersey City, NJ 07302
- United States
Scynexis Stock Performance
As of 19-Nov-2026, Scynexis’s stock price is $2.59. Its current market cap is $25.9M with 10M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.59 | $2.82 | $2.51 - $9.12 | $25.9M | 10M | 224K | -$0.23 |
Scynexis Financials Summary
As of 30-Sep-2026, Scynexis has a trailing 12-month revenue of $18.9M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | (2,987) | (9,105) | (7,019) | 9,707 |
| Revenue | 18,881 | 20,601 | 3,746 | 140,141 |
| EBITDA | (12,306) | (10,613) | (24,600) | 66,935 |
| Net Income | (10,102) | (8,609) | (21,288) | 67,041 |
| Total Assets | 67,951 | 59,027 | 90,643 | 128,412 |
| Total Debt | 1,821 | 2,175 | 16,270 | 15,080 |
Scynexis Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Scynexis Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Scynexis Comparisons
Industry
Financing
Details
Scynexis Competitors (35)
One of Scynexis’s 35 competitors is Spero Therapeutics, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Spero Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Peloton Therapeutics | Formerly VC-backed | Dallas, TX | ||||
| F2G | Venture Capital-Backed | Macclesfield, United Kingdom | ||||
| Paratek Pharmaceuticals | Private Equity-Backed | King of Prussia, PA | ||||
| Melinta Therapeutics | Private Equity-Backed | Parsippany, NJ |
Scynexis Patents
Scynexis Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4836771-A1 | Triterpenoid antifungals for use in the treatment of mucormycosis | Pending | 05-Jan-2024 | ||
| WO-2025147685-A1 | Triterpenoid antifungals for use in the treatment of mucormycosis | Inactive | 05-Jan-2024 | ||
| AU-2021250655-A1 | Use of a thienopyridone derivative in the treatment of autosomal dominant polycystic kidney disease (adpkd) | Active | 02-Apr-2020 | ||
| AU-2021250655-B2 | Use of a thienopyridone derivative in the treatment of autosomal dominant polycystic kidney disease (adpkd) | Active | 02-Apr-2020 | ||
| US-12310949-B2 | Use of a thienopyridone derivative in the treatment of autosomal dominant polycystic kidney disease (adpkd) | Active | 02-Apr-2020 | A61K31/4365 |
Scynexis Signals
Scynexis Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Scynexis Investments (1)
Scynexis’s most recent deal was a Corporate Asset Purchase with Poxel (SCY-770) for . The deal was made on 31-Mar-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Poxel (SCY-770) | 31-Mar-2026 | Corporate Asset Purchase | Buildings and Property |
Scynexis ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Scynexis FAQs
-
When was Scynexis founded?
Scynexis was founded in 1999.
-
Where is Scynexis headquartered?
Scynexis is headquartered in Jersey City, NJ.
-
What is the size of Scynexis?
Scynexis has 29 total employees.
-
What industry is Scynexis in?
Scynexis’s primary industry is Drug Discovery.
-
Is Scynexis a private or public company?
Scynexis is a Public company.
-
What is Scynexis’s stock symbol?
The ticker symbol for Scynexis is SCYX.
-
What is the current stock price of Scynexis?
As of 19-Nov-2026 the stock price of Scynexis is $2.59.
-
What is the current market cap of Scynexis?
The current market capitalization of Scynexis is $25.9M.
-
What is Scynexis’s current revenue?
The trailing twelve month revenue for Scynexis is $18.9M.
-
Who are Scynexis’s competitors?
Spero Therapeutics, Peloton Therapeutics, F2G, Paratek Pharmaceuticals, and Melinta Therapeutics are some of the 35 competitors of Scynexis.
-
What is Scynexis’s annual earnings per share (EPS)?
Scynexis’s EPS for 12 months was -$0.23.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process